Zacks Research Issues Negative Estimate for Avantor Earnings

Avantor, Inc. (NYSE:AVTR) – Research analysts at Zacks Research lowered their Q2 2026 earnings estimates for Avantor in a report released on Wednesday, February 5th. Zacks Research analyst D. Dey now anticipates that the company will post earnings of $0.28 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Avantor’s current full-year earnings is $0.98 per share.

Several other research firms have also recently weighed in on AVTR. Barclays decreased their price objective on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a report on Monday. UBS Group reissued a “neutral” rating and set a $25.00 price objective (down from $29.00) on shares of Avantor in a report on Friday, January 17th. Robert W. Baird decreased their price objective on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 28th. Wells Fargo & Company decreased their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Monday. Finally, Morgan Stanley cut their target price on shares of Avantor from $27.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Avantor has an average rating of “Moderate Buy” and a consensus price target of $26.15.

Avantor Stock Down 0.9 %

AVTR opened at $19.00 on Monday. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The firm has a 50 day moving average price of $21.73 and a 200-day moving average price of $23.47. Avantor has a twelve month low of $18.49 and a twelve month high of $28.00. The stock has a market capitalization of $12.93 billion, a price-to-earnings ratio of 41.30, a PEG ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR) last issued its earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period in the previous year, the firm earned $0.22 earnings per share.

Hedge Funds Weigh In On Avantor

Hedge funds and other institutional investors have recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB boosted its position in shares of Avantor by 99.5% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,253 shares of the company’s stock worth $26,000 after acquiring an additional 625 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock worth $34,000 after acquiring an additional 830 shares during the last quarter. UMB Bank n.a. bought a new position in shares of Avantor during the third quarter worth $49,000. Global Retirement Partners LLC boosted its position in shares of Avantor by 76.7% during the fourth quarter. Global Retirement Partners LLC now owns 2,459 shares of the company’s stock worth $52,000 after acquiring an additional 1,067 shares during the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Avantor by 69.6% during the third quarter. Nisa Investment Advisors LLC now owns 2,035 shares of the company’s stock worth $53,000 after acquiring an additional 835 shares during the last quarter. Institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.